3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
27
Cyclophosphamide
14
Gemcitabine
13
fludarabine
11
Carboplatin
10
aldesleukin
9
Trastuzumab
9
Specimen Handling
9
Nivolumab
9
Magnetic Resonance Spectroscopy
8
Biopsy
8
olaparib
7
Cisplatin
7
Paclitaxel
6
palbociclib
5
atezolizumab
5
Taxes
5
Early Intervention, Educational
5
Oxaliplatin
4
Methods
4
Irinotecan
4
Drug Therapy
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
talazoparib
3
spartalizumab
3
pertuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Mebendazole
×
Gynecologic
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn